Skip to main content
Inify Laboratories AB logo

Inify Laboratories AB — Investor Relations & Filings

Ticker · INIFY ISIN · SE0017486103 LEI · 549300306YYJ3BX3VB98 ST Human health and social work activities
Filings indexed 339 across all filing types
Latest filing 2025-05-21 AGM Information
Country SE Sweden
Listing ST INIFY

About Inify Laboratories AB

https://www.inify.com/

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. The company utilizes a fully digital, standardized, and AI-supported workflow for histopathology analysis. This integrated service model is designed to optimize the entire diagnostic process, from sample receipt to final report, ensuring high quality and significantly reduced turnaround times for clinical partners. Initially focused on prostate cancer, the company has expanded its diagnostic capabilities to include other areas such as gastroenterology. By streamlining the clinical pathway, Inify Laboratories enables healthcare providers to receive faster results, which facilitates earlier patient follow-up and treatment planning.

Recent filings

Filing Released Lang Actions
Inify Laboratories AB (publ) - kommuniké från årsstämma
AGM Information Classification · 98% confidence The document title is "Inify Laboratories AB (publ) - kommuniké från årsstämma," which translates to 'Inify Laboratories AB (publ) - announcement from the Annual General Meeting (AGM).' The text details decisions made at the AGM, including the approval of financial statements for the period 2024-01-01 - 2024-12-31, decisions on remuneration, re-election of board members and auditors, and changes to the articles of association. This content directly corresponds to the definition of AGM Information (AGM-R). Although it summarizes the meeting, it is the official communication of the results, fitting the AGM-R code better than a general Regulatory Filing (RNS) or a Proxy Solicitation (PSI) which precedes the meeting.
2025-05-21 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Kvartalsrapport första kvartalet 2025' (Quarterly Report for the first quarter of 2025) for Inify Laboratories AB. It contains comprehensive financial data, including income statements, balance sheet metrics, cash flow analysis, and management commentary on business performance, growth, and outlook. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2025
2025-04-30 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the first quarter 2025' and contains comprehensive financial statements, key performance indicators (EBITDA, net sales, earnings per share), management commentary on business operations, and financial position analysis. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-04-30 English
Inify Laboratories: Continued strong growth - construction and establishment in the UK
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the first quarter 2025' and contains comprehensive financial statements, key performance indicators (EBITDA, net sales, earnings per share), management commentary on business operations, and financial position analysis. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-04-30 English
Inify Laboratories: Fortsatt stark tillväxt - uppbyggnad och etablering i Storbritannien
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Kvartalsrapport första kvartalet 2025' (Quarterly Report for the first quarter of 2025) for Inify Laboratories AB. It contains comprehensive financial data, including income statements, balance sheet metrics, cash flow analysis, and management commentary on business performance, growth, and outlook. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2025
2025-04-30 Swedish
Inify Laboratories: Fortsatt sterk vekst - bygging og etablering i Storbritannia
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the first quarter 2025' and contains comprehensive financial statements, key performance indicators (EBITDA, net sales, earnings per share), management commentary on business operations, and financial position analysis. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-04-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.